BRAF and neoplasm: While the V600E mutation in melanoma is approved for therapy with BRAF inhibitors dabrafenib and vemurafenib, these same inhibitors are controversial in other malignancies and they seem not able to inhibit tumorigenesis in pediatric astrocytomas harboring BRAF fusions and may even lead to tumor progression [103].